T 0039/23 16-05-2024
Download and more information:
CRYSTALLINE FORMS OF AN ANDROGEN RECEPTOR MODULATOR
Aragon Pharmaceuticals, Inc.
Sloan-Kettering Institute for Cancer Research
SANDOZ AG
Scorpio IP Limited
I. The appeals of opponents 1 and 2 (hereinafter appellants 1 and 2) lie from the decision of the opposition division to reject the oppositions against European patent EP 3 348 553.
II. During oral proceedings before the board, held as scheduled in the presence of all parties on 16 May 2024, the patent proprietors withdrew their consent and agreement under Article 113(2) EPC to the text of the patent as granted and also withdrew all requests on file.
1. Under Article 113(2) EPC, the European Patent Office shall examine, and decide upon, the European patent only in the text submitted to it, or agreed, by the proprietor of the patent.
2. The patent proprietors withdrew their consent and agreement to the text of the patent as granted. Furthermore, all requests pending in the appeal proceedings were also withdrawn. Consequently, there is no text of the patent submitted or agreed by the proprietor of the patent, on the basis of which the board can consider compliance with the requirements of the EPC.
3. It is established case law of the Boards of Appeal
since decision T 73/84 (OJ EPO 1985, 241) that under
such circumstances, the patent is to be revoked without
further substantive examination.
4. There are also no further ancillary issues that need to be dealt with by the board in the present case.
For these reasons it is decided that:
1. The decision under appeal is set aside.
2. The patent is revoked.